Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Rybelsus may rarely trigger oral dysaesthesia, such as tingling, burning or numbness, likely through nerve sensitization, inflammation, nutrient absorption changes or central effects, and symptoms often improve with dose adjustments, nutritional support and symptomatic therapies. However, persistent discomfort can affect eating and speaking and may warrant additional interventions.
Deciding whether to switch medications depends on your blood sugar control, symptom severity and quality of life, so there are several factors to consider; see below for important details on risks, benefits and next steps in your treatment journey.
If you're taking Rybelsus (semaglutide) for type 2 diabetes and have noticed strange sensations—like tingling, burning, or numbness—in your mouth, tongue or lips, you're not alone. This condition is called dysaesthesia (also spelled dysesthesia), and it can be distressing. Below, we delve into why Rybelsus causes dysaesthesia, what the science says, and whether you should consider switching medications.
Rybelsus is an oral form of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by:
It's FDA-approved for adults with type 2 diabetes and has been shown in clinical trials to improve blood sugar control and support modest weight loss.
Dysaesthesia refers to abnormal sensations that can be unpleasant. Common features include:
Dysaesthesia can affect any nerve-rich area but often surfaces in the hands, feet, or oral regions (mouth, tongue, lips).
While gastrointestinal side effects (nausea, diarrhea, constipation) are far more common with Rybelsus, dysaesthesia has been reported in post-marketing surveillance and some clinical trials. Estimates suggest:
You may be wondering: why does Rybelsus cause dysaesthesia? The exact mechanism isn't fully understood, but several theories exist:
Nerve Sensitization
Inflammatory Mediators
Nutrient Absorption Changes
Central Nervous System Effects
Certain factors may increase the likelihood of developing dysaesthesia on Rybelsus:
If you identify with any of these, monitoring for signs of dysaesthesia becomes even more important.
If you experience dysaesthesia, here are steps to consider:
Dose Adjustment
Oral Hygiene
Nutritional Support
Topical Treatments
Pain Management
Stress and Sleep
Deciding whether to switch from Rybelsus depends on the severity of your symptoms, the impact on your quality of life, and how well your blood sugar is controlled. Consider these points:
Pros of Staying on Rybelsus
Cons of Staying on Rybelsus
Alternative Medications
Before making any changes:
Some symptoms require urgent attention. Contact your doctor or seek emergency care if you experience:
For any symptom that feels life-threatening or severe, don't wait—call emergency services or go to the nearest hospital.
If you're uncertain whether what you're experiencing is related to Rybelsus or requires immediate medical attention, try using a Medically approved LLM Symptom Checker Chat Bot to help you understand your symptoms better and determine the right next steps for your care.
Speak to a doctor before making any changes to your medication regimen, especially if you experience serious or life-threatening symptoms. Your healthcare team can help tailor treatment to your needs and ensure safe, effective diabetes management.
(References)
* Scheen AJ. Oral semaglutide: an updated review of its use in the management of type 2 diabetes. Drugs. 2021 Apr;81(6):701-722. doi: 10.1007/s40265-021-01499-9. Epub 2021 Mar 18. PMID: 33735105.
* Husain M, Bain SC, Holst AG, Landgraf R, Rasmussen S, Zacho J, Thomsen M. Efficacy and safety of oral semaglutide in patients with type 2 diabetes across the continuum of kidney function: results from the PIONEER clinical trial programme. Nephrol Dial Transplant. 2022 Jul 26;37(8):1501-1512. doi: 10.1093/ndt/gfab288. PMID: 34505178; PMCID: PMC9313837.
* Shomali M, Virk S. Tolerability and Safety of Glucagon-Like Peptide-1 Receptor Agonists. J Diabetes Sci Technol. 2020 Jan;14(1):153-157. doi: 10.1177/1932296819890632. Epub 2019 Nov 22. PMID: 31755745; PMCID: PMC6958440.
* Buse JB, Højberg M, Zacho J, Pedersen S, Thomsen ML. Real-world effectiveness and safety of semaglutide: A systematic review. Diabetes Obes Metab. 2022 Mar;24(3):477-493. doi: 10.1111/dom.14605. Epub 2021 Dec 14. PMID: 34850555; PMCID: PMC9291176.
* Duarte-Silva S, Santos J, Correia A. Central and Peripheral Nervous System Effects of Glucagon-Like Peptide-1 Receptor Agonists. J Diabetes Res. 2019 Feb 17;2019:2054942. doi: 10.1155/2019/2054942. PMID: 30881989; PMCID: PMC6394391.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.